Skip to main content
. Author manuscript; available in PMC: 2024 Oct 17.
Published in final edited form as: Leuk Lymphoma. 2020 Jun 12;61(10):2488–2491. doi: 10.1080/10428194.2020.1775215

Figure 1. Overall survival of CLL patients with IFI on ibrutinib.

Figure 1.

10 of 21 patients were deceased at date of last follow-up (≥ 6 months for each patient; average 36.79 months of follow up). The first 5 deaths (4 in the first month and 1 in the fourth month) were IFI-related, while the other 5 deaths were due to disease progression or other causes.